Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3857570

Cc1ccc(C(=O)N2CC[C@@H](N)C2)cn1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.48
LMNA P02545 1/20 0.48
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
GRM5 P41594 1/20 0.45
PDE2A O00408 1/20 0.45
PADI4 Q9UM07 1/20 0.45
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
ABL1 P00519 1/20 0.42
KDM1A O60341 5/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857604 0.92 ALDH1A1 (0.55) KCNH2LMNAALDH1A1KMT2AMEN1
SCHEMBL5909143 0.92 ALDH1A1 (0.55) KCNH2LMNAALDH1A1KMT2AMEN1
SCHEMBL5744752 0.92 ALDH1A1 (0.55) KCNH2LMNAALDH1A1KMT2AMEN1
SCHEMBL14731432 0.84 ALDH1A1 (0.61) LMNAALDH1A1KMT2AMEN1GRM5
SCHEMBL2431433 0.84 GRM5 (0.53) LMNAALDH1A1KMT2AMEN1GRM5
SCHEMBL26944349 0.80 GRM5 (0.54) LMNAALDH1A1KMT2AMEN1GRM5
SCHEMBL5909235 0.78 ALDH1A1 (0.60) LMNAALDH1A1KMT2AMEN1GRM5
SCHEMBL12426729 0.77 KCNH2 (0.50) KCNH2GRM5KDM1A
SCHEMBL5908999 0.77 ALDH1A1 (0.61) LMNAALDH1A1KMT2AMEN1GRM5
Trifluoroacetic Acid SCHEMBL6824444 0.76 ALDH1A1 (0.57) LMNAALDH1A1KMT2AMEN1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592466-B2 Ureas having antiangiogenic activity ABBOTT LABORATORIES (US) 2009-09-22 US disclosed
EP-1680415-B1 PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20060160806-A1 N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea ABBVIE INC. 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160806-A1 N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea FLT4, FLT1, KDR KCNH2 4499/4885LMNA 2101/4885ALDH1A1 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.